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Abstract
Background: Viral replication as well as an immunopathological component are assumed to be
involved in the development of coxsackie B virus (CBV)-induced myocarditis. We observed that
mycophenolic acid (MPA), the active metabolite of the immunosuppressive agent mycophenolate
mofetil (MMF), inhibits coxsackie B3 virus (CBV3) replication in primary Human myocardial
fibroblasts. We therefore studied whether MMF, which is thus endowed with a direct antiviral as
well as immunosuppressive effect, may prevent CBV-induced myocarditis in a murine model.
Results: Four week old C3H-mice were infected with CBV3 and received twice daily, for 7
consecutive days (from one day before to 5 days post-virus inoculation) treatment with MMF via
oral gavage. Treatment with MMF resulted in a significant reduction in the development of CBV-
induced myocarditis as assessed by morphometric analysis, i.e. 78% reduction when MMF was
administered at 300 mg/kg/day (p < 0.001), 65% reduction at 200 mg/kg/day (p < 0.001), and 52%
reduction at 100 mg/kg/day (p = 0.001). The beneficial effect could not be ascribed to inhibition of
viral replication since titers of infectious virus and viral RNA in heart tissue were increased in MMF-
treated animals as compared to untreated animals.
Conclusion: The immunosuppressive agent MMF results in an important reduction of CBV3-
induced myocarditis in a murine model.
Background
Viral myocarditis is a common pathological condition
detected in approximately 1% of unselected asympto-
matic individuals [1]. Many viruses have been shown to
be involved as causative agents, but the principal agents
belong to enteroviruses in general and coxsackieviruses in
particular [2,3]. The proportion of cases of myocarditis
with coxsackieviral ethiology varies but can in 25–50% of
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the cases be attributed to coxsackie B group viruses (CBV)
[4,5]. Although most enterovirus-related cardiac illnesses
are subclinical, severe arrythmias and sudden cardiac
death may appear. About 10 to 20% of symptomatic
patients will eventually develop chronic cardiac disease,
which may progress to dilated cardiomyopathy, a severe
pathological condition, often requiring heart transplanta-
tion [6-8]. Overall, the enteroviral genome is present in
the hearts of 15–20% of patients with dilated cardiomy-
opathy [4,5,9,10]. Both direct viral injury and the
immune response of the host are believed to play a role in
the pathogenesis of viral heart disease [11]. Recent studies
in mouse models show that direct viral-induced damage
to the heart is necessary to cause CBV3-induced myocardi-
tis [12,13] and that a scenario of 'molecular mimicry' is
believed to be unlikely [14]. There is a prepondorance of
evidence that cytotoxic T lymphocytes are involved in
CBV3-induced myocarditis [15,16]. A therapeutic strategy
against coxsackievirus myocarditis may therefore ideally
be a combination of antiviral and immunosuppressive,
ideally lymphocyte-selective, therapy. Mycophenolate
mofetil (MMF), [the morpholinoethyl ester of mycophe-
nolic acid (MPA)] is an immunosupressive agent that is
used with success in the prevention of acute renal allograft
rejection and in the treatment of refractory rejection in
renal, heart and liver transplant patients [17,18]. MMF is
hydrolysed to MPA, the active immunosuppressive mole-
cule, which is a potent inhibitor of inosine monophos-
phate dehydrogenase (IMP-DH). The latter enzyme is key
in de novo purine synthesis and is responsible for the con-
version of IMP through XMP to GMP. Since IMP repre-
sents an important intermediate in the generation of
guanine-based nucleotides, MPA causes depletion of
intracellular guanine nucleotide pools, which are respon-
sible for the immunosuppressive effect of the drug [19]. T
and B lymphocytes are singularly dependent on the de
novo pathway for purine synthesis, what explains the lym-
phocyte-selective antiproliferative effects of MPA [19-23].
We earlier reported on the broad-spectrum antiviral activ-
ity of MPA and demonstrated that the molecule inhibits
CBV replication in vitro [24]. Since MMF is thus endowed
with both a direct inhibitory effect on CBV replication (in
vitro), as well as with an immunosuppressive effect, we
decided to study the effect of treatment with MMF in a
murine model for CBV-induced myocarditis.
Results
In vitro anti-CBV3 activity of MPA
Both MPA and ribavirin inhibit the in vitro replication of
CBV3 in Vero and HMF cells. The EC50-values for inhibi-
tion of CBV3 replication in Vero cells by ribavirin was 117
µg/ml and 55 µg/ml by MPA. In HMF cells EC50-values of
ribavirin and MPA were 250 µg/ml and 80 µg/ml, respec-
tively. In virus yield assays, MPA and ribavirin (both at
100 µg/ml) reduced viral yield by 89% and 87%, respec-
tively (Table 1).
Effect of MMF on CBV3-induced myocarditis
C3H/HeNHsd mice were infected intraperitoneally with
CBV3 and were treated by oral gavage twice daily for a
period of 6 consecutive days (starting one day before virus
inoculation) with either 100, 200 or 300 mg/kg/day of
MMF. The interferon inducer Poly IC [15 mg/kg/day once
a day, given intraperitoneally for 3 consecutive days, i.e.
on day one before virus inoculation, on the day of virus
inoculation and one day after virus inoculation] was used
as a positive control. No signs of toxicity of the com-
pounds were noted in treated animals. In a parallel toxic-
ity experiment, the body weight of drug-treated
uninfected young mice was monitored. Animals that
received treatment with MMF at 200 or 300 mg/kg/day
showed some growth retardation, but appeared otherwise
healthy. The bodyweight of mice that received either 200
mg/kg/day or 300 mg/kg/day of MMF for 5 consecutive
days was respectively 117% and 108% of their body
weight on day 0. The bodyweight of mice that had
received vehicle only for 5 consecutive days was 132% of
their body weight on day 0. All infected mice were sacri-
ficed on day 7 post-virus inoculation and the severity of
the myocarditis was assessed by morphometrical analysis
(Fig. 1). A dose of 300 mg/kg/day MMF resulted in 78%
reduction of the myocarditis score (p < 0.001), a 200 mg/
kg/day dose of MMF resulted in 65% reduction (p <
0.001), and a dose of 100 mg/kg/day of MMF resulted in
Table 1: Effect of ribavirin and MPA on CBV3 replication in Vero cells and human myocardial fibroblasts (HMF)
EC50 (µg/ml)a Yield reductionb (%) MTC (µg/ml)c
Vero HMF
M P A 5 58 08 9 2 0 0
Ribavirin 117 250 87 >500
aConcentration of compound that reduces viral induced cytopathic effect by 50% bReduction of virus yield in Vero cells in the presence of 100 µg/
ml of either compound cAs determined in Vero cells. Minimal toxic concentration, or correlation required to other normal cell morphologyBMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/25
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a reduction of 52% of the myocarditis foci (p = 0.001).
The interferon inducer poly IC reduced the severity of
myocarditis by 97% (p < 0.001). Prednisone, another
immunosuppressive agent was included as a control. Mice
received the compound at a dose of 15 mg/kg/day by
intraperitoneal injections starting one day before the virus
inoculation, until day 5 post-virus inoculation. In contrast
to what was observed for MMF, treatment with pred-
nisone resulted in an aggravation of the myocarditis, with
a 75% increase in the number of myocardial foci (p =
0.004).
Immunosuppressive effect of MMF
To verify whether MMF at the highest and most effective
dose used (i.e. 300 mg/kg/day), indeed suppressed the
immune system in C3H mice, a flow cytometric analysis
was carried out on cells isolated from spleen and blood of
(i) CBV3 infected mice (at day 7 post-virus inoculation)
that had been treated with 300 mg/kg/day of MMF for 7
consecutive days (n = 2) (ii) uninfected mice that had
received treatment with 300 mg/kg/day of MMF for 7 con-
secutive days (n = 2) (iii) CBV3 infected but untreated
mice (n = 2) and (iv) uninfected untreated mice (n = 2). A
significant drop (50%) in the number of CD19+ cells was
observed in spleen of MMF treated infected mice as com-
Effect of treatment with MMF or the interferon inducer poly IC on coxsackie virus B3 induced myocarditis in C3H mice Figure 1
Effect of treatment with MMF or the interferon inducer poly IC on coxsackie virus B3 induced myocarditis in 
C3H mice. Infected mice (two independent experiments) were treated via oral gavage for 7 consecutive days (-1, 0, 1, 2, 3, 4, 
5 relative to virus inoculation) with MMF at the indicated doses [(100 (n = 9), 200 (n = 10) or 300 (n = 6) mg/kg/day)]. Poly IC 
was given intraperitoneally at 15 mg/kg/day on days -1, 0, 1 relative to virus inoculation. Animals were sacrificed on day 7 post-
virus inoculation and the severity of the myocarditis lesions was assessed morphometrically. The virus control group consisted 
of 8 animals. Statistical differences were calculated between each experimental condition and the mock treated controls (*: p < 
0.05; **: p < 0.01: ***: p < 0.001).
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pared to untreated infected mice (Fig. 2), indicating severe
B-cell depletion. No significant effect of MMF administra-
tion on the numbers of CD4+ and CD8+ cells in spleen in
the different groups of mice was observed (data not
shown).
Effect of MMF on viral titers in heart
C3H/HeNHsd mice were infected intraperitoneally with
CBV3 and were treated two times daily for a period of 7
consecutive days (starting one day before virus inocula-
tion) with either 100, 200 or 300 mg/kg/day of MMF.
Hearts were dissected on day 6 post-virus inoculation and
viral load was determined by monitoring (i) the titer of
infectious virus, as well as (ii) the levels of viral RNA by
quantitative real-time RT-PCR. In contrast to expectations,
a significant increase was noted in viral RNA levels in
heart homogenates of animals that had been treated with
either 100 mg/kg/day of MMF (28%, p < 0.001), 200 mg/
kg/day of MMF (17%, p = 0.04) or 300 mg/kg/day of MMF
(16%, p = 0.003) as compared to infected untreated con-
trols (Fig. 3).
Discussion
Recent studies have shown that both direct viral induced
damage, as well as immunopathological factors, are
involved in coxsackievirus induced myocarditis [11,12].
We therefore hypothesised that a molecule that would
have an inhibitory effect on both the immune system and
on viral replication, may be efficient in preventing the
development of CBV-induced myocarditis. Earlier we
Effect of MMF on the number of CD19+ cells in the spleen of C3H mice Figure 2
Effect of MMF on the number of CD19+ cells in the spleen of C3H mice. Flow cytometric analysis on cells isolated 
from the spleen of (i) uninfected untreated mice (ii) CBV infected mice [at day 7 post infection] that had been treated with 300 
mg/kg/day of MMF for 7 consecutive days (iii) uninfected mice that had received treatment with 300 mg/kg/day of MMF for 7 
consecutive days and (iv) CBV3 infected but untreated mice. Samples from two mice were pooled for analysis.
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observed that the replication of various RNA viruses can
be inhibited by mycophenolic acid (MPA), the active
component of mycophenolate mofetil [24]. MPA, which
is a potent inhibitor of IMP-dehydrogenase depletes intra-
cellular GTP pools thereby inhibiting viral RNA synthesis
and as a consequence viral replication. MMF is a well
known immunosuppressive agent that is being used in a
variety of organ transplantations [25]. In the murine
model for acute myocarditis treatment with MMF resulted
in a marked and dose dependent reduction in the severity
of the virus induced myocarditis. In marked contrast to
MMF, prednisone, which was included as an example of
another immunosuppressive agent, resulted in a signifi-
cant increase in the number of myocarditis lesions. This is
consistent with earlier studies where it was shown that
corticosteroids increase the severity of the disease during
the acute phase of viral myocarditis in murine models
[26,27]. In contrast to expectations, and despite the pro-
tective effect of MMF on the progression of the myocardi-
tis, RNA levels in heart tissue were markedly increased in
MMF treated animals. This can only be explained if the
antiviral effect of MPA is not potent enough or if the phar-
macokinetic profile of the molecule is not favourable
enough to allow MPA to elicit an antiviral effect in vivo. In
addition, the immunosuppressive effect of MMF may
"neutralize" its own antiviral effect since viral replication
will not, or not more efficiently, be controlled by the
immune system of the host. It remains puzzling, however,
why MMF (despite the fact that it results in an increase in
viral RNA levels in the heart), is able to reduce the severity
of viral induced myocarditis, whereas prednisone,
another immunosuppressive agent, aggravates the disease
Effect of MMF on viral RNA load monitored by quantitative RT-PCR in the heart of CBV3-infected C3H mice Figure 3
Effect of MMF on viral RNA load monitored by quantitative RT-PCR in the heart of CBV3-infected C3H mice. 
The different groups consisted of infected mice that had either been left untreated or that had been treated with MMF (at 100, 
200 or 300 mg/kg/day). Each group consisted of 4 animals (*: p < 0.05; **: p < 0.01: ***: p < 0.001).
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in the same model. Other studies with murine models for
CBV3 induced myocarditis show that therapy with immu-
nosuppressive drugs, such as FK-506 and cyclophospha-
mide early in the course of acute viral myocarditis tend to
be unfavorable for the host, resulting in higher virus titers
in the heart, higher mortality rate but sometimes with a
apparent reduction of myocardial infiltration [28-30]. The
role of virus-induced damage in initiating CBV3-induced
myocarditis and the benefit of reducing the level of
viremia early during infection has been recently stressed
[12,14]. We here observed an important B-cell, but not T-
cell depletion in MMF treated infected mice. B lym-
phocytes appear central in the interaction between Cox-
sackieviruses (CVB) and their mammalian hosts. Lack of
antibody production by agammaglobulinemic humans is
responsible for their enhanced susceptibility to chronic
infections by CVB's [31,32] and related enteroviruses [33].
Several studies have shown that B lymphocytes can be
productively infected by CVB, suggesting the role of these
cells in virus dissemination and/or modulation of the
host immune response [34-36]. Antibodies directed
against CBV resulte, when administered to CBV infected
to mice in either (i) a protective effect [37], (ii) induction
of cardiopathologic alterations [38], (iii) initial protec-
tion via virus clearance with subsequent stimulation of
proinflammatry reactions and sustained myocarditis [39],
and (iv) antibody-mediated immune enhancement
[40,41]. Our observations support this complex picture of
the role of B lymphocytes in CVB3-induced myocarditis.
The effects of WIN 54954, a specific inhibitor of enterovi-
ral replication, in CBV-induced myocarditis in a mouse
model, were attributed to its inhibitory effects on viral
replication without interference with cellular or humoral
immunity [42]. Recently, we demonstrated that also 2-
(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860), a
broad spectrum anti-picornavirus compound is able to
markedly reduce the development of CBV3-induced myo-
carditis [43]. Also the interferon inducers Ampligen and
poly IC were shown to efficiently inhibit CBV3 replication
in the heart and to have, as a result, an important inhibi-
tory effect on progression of viral myocarditis [44]. From
these studies and from the data presented, it may be
assumed that the combined use of a potent and selective
inhibitor of CBV replication, together with MMF may
result in a protective synergistic effect on the progression
of the viral myocarditis. Although we initially hypothe-
sized that MMF may have a dual effect (i.e. reduction of
the immunopathological component as well as reduction
of viral titers) on CBV-induced myocarditis, the protective
effect of MMF as noted here, is apparently solely attribut-
able to a reduction of the immunopathological
component.
Conclusions
We conclude that the immunosuppressive agent MMF
results in a marked and dose dependent reduction in the
severity of CBV3-induced myocarditis in a murine model.
Howerer, we do not advise the use of this drug as a single
therapy for this pathological condition because of the
increase in the viral titers in the heart under MMF treat-
ment. However, combination therapy with selective anti-
virals, if these would become available, may be an
interesting option. Despite the fact that MPA, the meta-
bolically active component of MMF, elicits in vitro activity
against CBV3, the protective effect of MMF on CBV3-
induced myocarditis in mice is apparently solely due to its
immunosuppressive effects.
Methods
Cells and viruses
Coxsackievirus B3 (CBV3) (Nancy strain) was obtained
from the American Type Culture Collection (ATCC: VR-
30). CBV3 was propagated in Vero cells. Human myocar-
dial fibroblasts of pediatric origin (HMF) were prepared
from parts of myocardial tissue [kindly provided by Dr. B.
Meyns (Cardiovascular Surgery Unit, University Hospi-
tals, Leuven, Belgium), and obtained from the surgery for
Fallot-tetralogy] that was digested with trypsine (Gibco,
Life Technologies, Rockville, MD). HMF and Vero cells
were propagated in minimal essential medium (MEM;
Gibco, Life Technologies, Rockville, MD) supplemented
with 10% fetal calf serum (FCS; Integro, Zaandam, The
Netherlands), 1% L-glutamine (Gibco, Life Technologies,
Rockville, MD), and 0.3% sodium bicarbonate (Gibco,
Life Technologies, Rockville, MD).
Compounds
Mycophenolic acid (MPA) was purchased from Sigma (St.
Louis, Mo., USA). MMF was kindly provided by Roche
(Palo Alto, California, USA).
Antiviral assays
Human myocardial fibroblasts (HMF) or Vero cells were
grown to confluency in microtiter trays (final cell density:
≈ 105 cell/well) and were infected with an input of CBV3
that caused ≈ 100% CPE at 5 days postinfection (500
CCID50). Virus was removed following a 2-h virus adsorp-
tion period after which serial dilutions of the compounds
were added. Virus-induced cytopathic effect (CPE) in
HMF was recorded microscopically at 5 days post infec-
tion following fixation with 70% ethanol and staining
with a 2% Giemsa solution (Merck, Darmstadt, Ger-
many). The CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay (MTS) was used to determine antiviral
activity in Vero cells and proliferation of uninfected Vero
cells. The MTS assay was performed according to the
instructions of the manufacturer (Promega Corporation,
Florida, USA). Briefly, 3-(4,5-dimethylthiazol-2-yl)-5-(3-BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/25
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carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium (MTS) is bioreduced by cells into a formazan that is
soluble in tissue culture medium after which absorbance
of the formazan is read at 490 nm. To measure the effect
on cell growth, cells were seeded (in MEM containing
10% FCS) at a density of 4000 cell/well in the presence of
serial dilutions of the compounds. Cells were allowed to
proliferate for 3 days after which the assay was read by
means of the MTS-method.
Virus yield assay
Confluent cultures of Vero cells were infected with a titer
of CBV3 that caused 100% CPE at 5 days post infection
and were treated (or left untreated) with serial dilutions of
the drugs. Cultures were harvested and frozen (-80°C) at
5 days postinfection. Following another freezing-thawing
cycle, cell debris was removed by centrifugation and serial
dilutions were inoculated on confluent Vero cell cultures.
Virus titers were determined 5 days later.
Virus titration from heart homogenate
Hearts were dissected on day 6 post-virus inoculation, a
time at which the highest viral titers were detected in
untreated controls in preliminary experiments (data not
shown). Serial dilutions of 10% (w/v) heart homogenates
were inoculated on confluent Vero cell cultures and virus
titers were determined 5 days later.
In vivo toxicity experiments
NMRI male mice [Centre d'Elevage, R. Janvier, France]
weighing 15 g were treated for 6 consecutive days, by
means of oral gavage, with mycophenolate mofetil
(MMF) at 200 mg/kg/day or 300 mg/kg/day in 0.2 ml
vehicle. Vehicle consisted of sodium chloride (0.9%),
sodium carboxymethylcellulose (0.5%), polysorbate 80
(0.4%), benzyl alcohol (0.9%) and distilled water
(97.3%).
Treatment of CBV3 infected mice
Four-week-old male C3H/HeNHsd mice (Harlan Labora-
tories, The Netherlands) weighing 15 g, were inoculated
intraperitoneally (i.p.) with 107 CCID50 of CBV3. MMF
was administered by oral gavage, twice daily (starting one
day before the virus inoculation until day 5 post-virus
inoculation) at doses of 100, 200 or 300 mg/kg/day in the
same vehicle as described for the toxicity experiments.
Poly IC was dissolved in sterile PBS and was administered
intraperitoneally, once a day for 3 consecutive days (one
day before virus inoculation, the day of virus inoculation
and one day after virus inoculation) at a dose of 15 mg/
kg/day. Body weight was monitored daily. To assess the
severity of acute CVB3-induced myocarditis, all animals
were sacrificed on day 7 post-virus inoculation (following
ether anesthesia). Hearts were fixed in 6% buffered for-
maldehyde. The heart was sliced parallel to the basis of
the organ into three pieces. Each of these were embedded
in paraffin and sectioned at 5 µm. Sections were subse-
quently stained with H & E and examined by light
microscopy.
Morphometry
The extension of myocarditis was determined in H & E-
stained sections of the heart of untreated, MMF-treated
and polyIC-treated animals by means of a conventional
point-counting method using an ocular grid containing
121 equally spaced points. Per grid 5 constant points were
counted either hitting or non-hitting an affected area and
this was done for 15 stratified random positions of the
grid. A myocarditis "score" was defined as the proportion
of points hitting the myocarditis area and is expressed in
%. The counting was performed for 3 sections per heart.
The counting resulted in a total of 75 points per heart. Sec-
tions were read at × 200.
Flow cytometric analysis
Spleens were removed and passed through cell strainers
(BD Labware, Franclin Lakes, NJ). Blood, taken by heart
puncture was collected on heparin. Erythrocytes were
removed from blood and splenocyte suspensions by lysis
with NH4Cl (0.83% in 0.01 M Tris-HCl, ph 7.2; two con-
secutive incubations of 5 and 3 minutes at 37°C).
Remaining cells were washed, resuspended in cold PBS,
counted and stained for flow cytometric analysis as
described [45]. Briefly, aliquots of 2 × 105 cells in 0.2 ml
were stained with either FITC-conjugated anti-CD8 and
PE-conjugated anti-CD4 or stained with FITC-conjugated
anti-CD19 and PE-conjugated anti-Mac-1 (CD11b). All
antibodies were purchased from R&D Systems Europe,
Abingdon, U.K. Cells were analysed with a FACScan flow
cytometer (BD Biosciences).
RNA isolation and cDNA synthesis
Heart homogenate of 10% (w/v) was used for the analy-
sis. RNA extraction was performed using the QIAamp
RNA Mini Kit (QIAGEN, Hilden, Germany) according to
the procedure described by the manufacturer. cDNA was
generated at 42°C for 45 minutes using 200 units M-MLV
reverse transcriptase (Gibco, Life Technologies, Rockville,
MD), 40 units rRNasin Rnase Inhibitor (Promega Corpo-
ration, Florida, USA), 5 µM random hexamer primers
(Amersham Pharmacia Biotech, Roosendal, The
Netherlands), 1 mM dNTPs (Gibco, Life Technologies,
Rockville, MD) and buffer containing 250 mM Tris HCl
(pH 8.3), 375 mM KCl and 15 mM Mg2+ (Gibco, Life
Technologies, Rockville, MD) following denaturation at
70°C for 10 minutes. The reaction was terminated by
heating at 99°C for 3 minutes.BMC Microbiology 2003, 3 http://www.biomedcentral.com/1471-2180/3/25
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Quantitative analysis of CBV3 RNA by real-time RT-
Taqman PCR
Real time PCR was performed on the ABI Prism™ 7700
Sequence Detection System (Applied Biosystems, Roche,
Branchburg, New Jersey, USA). Primers and probes were
developed using Primer Express software (Applied Biosys-
tems, Roche, Branchburg, New Jersey, USA). The primers
used are: forward primer 5'-ACGAATCCCAGTGT-
GTTTTGG-3', reverse primer 5'-TGCTCAAAAACGGTAT-
GGACAT-3' and Taqman probe 5'-
CGAGGGAAACGCCCCGCC-3'. The Taqman probe was
labelled at the 5' end with the reporter dye molecule FAM
(emission wavelength 518 nm) and at the 3' end with the
quencher dye TAMRA (emission wavelength 582 nm).
The 3' end of the probe was additionally phosphorylated
to prevent extension during PCR. Each PCR was
performed in 25 µl of PCR reagent mixture containing
0.25 µl of each primer (900 nM), 1 µl specific Taqman
probe (200 nM), 12.5 µl 2 x universal Master Mix
(Applied Biosystems, Roche, Branchburg, New Jersey,
USA), 6 µl water and 5 µl of sample. The PCR-reaction
consisted of a decontamination step (5 minutes at 50°C),
Taq-activation step (10 minutes at 94°C) and 50 cycles of
denaturation (10 seconds at 94°C) and annealing (1
minute at 60°C). For each PCR run, negative template and
positive template samples were used. The cycle threshold
value (Ct-value) is defined as the number of PCR cycles
for which the signal exceeds the baseline, which defines a
positive value. The sample was considered to be positive
if the Ct-value was <50. Results are expressed as genomic
equivalents (GE), being the amount of cDNA correspond-
ing to the amount of viral RNA.
Statistics
To assess differences in the number of heart lesions in
treated versus untreated animals, data were analysed by
means of the Student's t test.
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